Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

223
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
223
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

549
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
549
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

531
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
531
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

214
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
214
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

290
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
290

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Oxidative Capacity, but Not Oxidative Burden, Predicts Mortality Among Patients With End-Stage Kidney Disease.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·2026
Same author

Artificial Intelligence-Assisted Screening for Patients With Diabetic Retinopathy and Age-Related Macular Degeneration in Family Medicine and Geriatric and Gerontology Care: Protocol for a Pragmatic Randomized Clinical Trial.

JMIR research protocols·2026
Same author

Total kidney volume and frailty severity in ADPKD: A pilot observation.

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Response to comment on "Operationalizing vascular frailty: structural and functional vascular ageing as determinants of geriatric phenotypes".

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Functional interaction between advanced glycation end-products and IGFBP-3 contributes to renal pathology in aging-associated chronic kidney disease.

Tissue & cell·2026
Same author

Evidence-Based Assessment of Pesticide-Related Nephrotoxicity: Clinical Outcomes, Experimental Data, and Molecular Signatures.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jan 10, 2026

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

1.2K

Frailty Among Patients With ADPKD.

Jui Wang1,2, Szu-Ying Lee3, Chia-Ter Chao4,5,6,7

  • 1College of Public Health, Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan.

Kidney International Reports
|November 24, 2025
PubMed
Summary

Autosomal dominant polycystic kidney disease (ADPKD) did not increase the risk of developing or worsening frailty in this study. These findings suggest ADPKD does not independently drive functional decline beyond its kidney impact.

Keywords:
agingautosomal dominant polycystic kidney diseasechronic kidney diseasefrailtylongitudinal cohort studypropensity score matching

More Related Videos

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K
Frailty Assessment in an Aging Mouse Model
06:58

Frailty Assessment in an Aging Mouse Model

Published on: September 23, 2025

398

Related Experiment Videos

Last Updated: Jan 10, 2026

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

1.2K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K
Frailty Assessment in an Aging Mouse Model
06:58

Frailty Assessment in an Aging Mouse Model

Published on: September 23, 2025

398

Area of Science:

  • Nephrology
  • Geriatrics
  • Internal Medicine

Background:

  • Autosomal dominant polycystic kidney disease (ADPKD) is a leading inherited cause of end-stage kidney disease (ESKD).
  • Frailty is a state of increased vulnerability to adverse health outcomes, and its association with ADPKD is not well-established.
  • Understanding frailty risk in ADPKD is crucial for managing systemic complications and functional decline.

Purpose of the Study:

  • To investigate the association between ADPKD and the risk of incident or worsening frailty.
  • To determine if ADPKD independently contributes to the development or progression of frailty.

Main Methods:

  • Retrospective cohort study utilizing the National Taiwan University Hospital Integrate Medical Database (2006-2021).
  • Propensity score matching was used to compare patients with ADPKD against controls with simple kidney cysts (SKCs).
  • Frailty was assessed using the FRAIL scale, with survival analysis techniques employed to evaluate associations.

Main Results:

  • Over a median follow-up of 4.8 years, ADPKD was not significantly associated with an increased risk of incident frailty (HR: 1.20, 95% CI: 0.69-2.08).
  • Similarly, ADPKD did not show a significant association with worsening frailty (HR: 0.98, 95% CI: 0.82-1.17).
  • These findings were consistent across various subgroups and after accounting for competing risks.

Conclusions:

  • ADPKD is not associated with an increased risk of incident or worsening frailty in this propensity score-matched cohort.
  • The results suggest that ADPKD may not independently accelerate functional decline beyond its direct impact on kidney function.
  • Further research may explore other contributing factors to frailty in ADPKD patients.